An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available

Next Previous
Trial Profile

An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Polycythaemia vera
  • Focus Adverse reactions; Expanded access
  • Sponsors Novartis; Novartis Pharma A.G.

    • Most Recent Events

    • 21 Mar 2018 Status changed from recruiting to completed.
    • 12 Jan 2018 This trial has been completed in Bulgaria.
    • 12 Dec 2017 Safety and efficacy results (n=75; data cutoff: Jan 15, 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top